When living with metastatic colorectal cancer (mCRC)...
CYRAMZA can help keep you fighting for what matters to you
You're not the type who settles. You're the type who pushes for more. But where individual results with CYRAMZA can vary, clinical studies have shown…
CYRAMZA may help you live longer
56% of people lived 1 year or longer with CYRAMZA + FOLFIRI (a type of chemotherapy) vs 48% with chemotherapy alone
- Half of the people who received CYRAMZA + chemotherapy after their cancer progressed were still alive at 13.3 months vs 11.7 months with chemotherapy alone
CYRAMZA provided more time without disease progression
47% of people had delayed disease progression for 6 months or longer with CYRAMZA + chemotherapy vs 36% with chemotherapy alone
- Half of the people who received CYRAMZA + chemotherapy lived without their cancer getting worse for 5.7 months vs 4.5 months with chemotherapy alone
CYRAMZA was studied in a clinical trial of 1072 people with metastatic colorectal cancer who received CYRAMZA + FOLFIRI (536 people) vs those who received FOLFIRI alone (536 people). All people in the study had previously received bevacizumab, oxaliplatin, and a fluoropyrimidine (other types of chemotherapy).